The estimated Net Worth of Samuel Bates Martin is at least 3.89 百万$ dollars as of 14 June 2024. Samuel Martin owns over 20,169 units of Celldex Therapeutics stock worth over 1,886,167$ and over the last 6 years Samuel sold CLDX stock worth over 2,004,665$.
Sign up
Samuel Martin CLDX stock SEC Form 4 insiders trading
Samuel has made over 8 trades of the Celldex Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Samuel exercised 20,169 units of CLDX stock worth 204,917$ on 14 June 2024.
The largest trade Samuel's ever made was selling 35,000 units of Celldex Therapeutics stock on 30 May 2024 worth over 1,191,750$. On average, Samuel trades about 9,070 units every 98 days since 2018. As of 14 June 2024 Samuel still owns at least 45,297 units of Celldex Therapeutics stock.
You can see the complete history of Samuel Martin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Samuel Martin's mailing address?
Samuel's mailing address filed with the SEC is 53 I-78 Frontage Rd, Hampton, NJ 08827, USA.
Insiders trading at Celldex Therapeutics
Over the last 16 years, insiders at Celldex Therapeutics have traded over 19,527,314$ worth of Celldex Therapeutics stock and bought 273,450 units worth 1,157,166$ . The most active insiders traders include Rajesh B Parekh、Garry Arthur Neil、Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of 1,750,671$. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth 204,917$.
What does Celldex Therapeutics do?
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
What does Celldex Therapeutics's logo look like?
Complete history of Samuel Martin stock trades at Celldex Therapeutics
Celldex Therapeutics executives and stock owners
Celldex Therapeutics executives and other stock owners filed with the SEC include:
-
Ronald Pepin,
Senior Vice President and Chief Business Officer -
Anthony Marucci,
President, Chief Executive Officer, Director -
Anthony S. Marucci M.B.A.,
Founder, Pres, CEO & Director -
Tibor Keler,
Executive Vice President and Chief Scientific Officer -
Dr. Tibor Keler,
Founder, Chief Scientific Officer & Exec. VP -
Dr. Diane C. Young M.D.,
Sr. VP & Chief Medical Officer -
Margo Heath-Chiozzi,
Senior Vice President - Regulatory Affairs -
Sam Martin,
Chief Financial Officer, Senior Vice President, Secretary -
Richard Wright,
Senior Vice President, Chief Commercial Officer -
Dr. Margo Heath-Chiozzi M.D.,
Sr. VP of Regulatory Affairs -
Elizabeth Crowley,
Senior Vice President, Chief Product Development Officer -
Sam Martin,
Sr. VP, CFO, Sec. & Treasurer -
Elizabeth Crowley,
Chief Product Devel. Officer & Sr. VP -
Karen Shoos,
Independent Chairman of the Board -
Keith Brownlie,
Independent Director -
James Marino,
Independent Director -
Harry Penner,
Independent Director -
Herbert Conrad,
Independent Director -
Diane Young,
Senior Vice President, Chief Medical Officer -
Sarah Cavanaugh,
Senior Vice President - Corporate Affairs and Administration -
Prof. Joseph P. Schlessinger Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Richard M. Wright Ph.D.,
Chief Commercial Officer & Sr. VP -
Dr. Ronald A. Pepin,
Chief Bus. Officer & Sr. VP -
Freddy A. Jimenez Esq.,
Sr. VP & Gen. Counsel -
Patrick Till,
Sr. Director of Investor Relations & Corp. Communications -
Sarah Cavanaugh,
Sr. VP of Corp. Affairs & Admin. -
Theresa La Vallee,
SVP, Reg.& Precision Medicine -
Larry Ellberger,
Director -
George Elston,
Director -
Gerald Ph D Mc Mahon,
Director -
Avery W Catlin,
Sr. VP & CFO -
Den Broek Richard Van,
Director -
Rita Jain,
-
Timothy M Shannon,
Director -
Rajesh B Parekh,
Director -
Charles R Schaller,
Director -
Inc Medarex,
10% owner -
Ronald C Newbold,
Sr. VP, Business Dev. -
Cheryl Cohen,
-
Freddy A. Jimenez,
SVP & GENERAL COUNSEL -
Garry Arthur Neil,